Overview

* ImmuCell Q3 2025 product sales decreased by 8% yr/yr to $5.5 mln

* Company reported a net loss of $140,000 for Q3 2025

* Gross margin improved to 43% in Q3 2025 from 26% in Q3 2024

Outlook

* Company continues to collect market feedback on Re-Tain through 2026

* ImmuCell ( ICCC ) has sufficient inventory to drive product adoption and revenue growth

Result Drivers

* BACKLOG IMPACT - Previous production interruptions led to backlog issues affecting Q3 sales, per CFO Timothy C. Fiori

* GROSS MARGIN RECOVERY - Gross margin improved to 43% in Q3 2025 due to higher product sales and cost control, per CFO Timothy C. Fiori

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $5.51

Product mln

Sales

Q3 EPS -$0.02

Q3 Net -$140,00

Income 0

Q3 Basic -$0.02

EPS

Q3 $2.34

Operatin mln

g

Expenses

Q3 -$135,00

Pretax 0

Profit

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)